New drug combo aims to stop cervical Cancer's return
NCT ID NCT07167160
Summary
This study is testing whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy helps prevent cervical cancer from returning after surgery, specifically for patients whose cancer had spread to their lymph nodes. It will follow 59 participants for three years to see if the combination treatment keeps them cancer-free longer. The goal is to see if this approach provides better long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Women's Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.